Contents:

I. Introduction 1 II. A Network based Approach to KOL Management 2 i. Activating Networks: Pharma Market Needs & Drivers 2 III. Overall KOL Landscape Description of the US Breast Cancer Market 4 i. Starting Points 4 ii. Overview Mapping – Network Visualization 4 iii. Description of Key Landscape Characteristics 6 IV. KOL Affinity Cluster Analysis 8 i. Effective Targeting of KOLs by Affinity Cluster 8 ii. KOL Cluster Analysis – Network Visualization 9 iii. Description and Close-Ups of MD Cluster Details 11 iv. Most Influential KOL per Cluster - MD Cluster Allocation 21 V. Key Actor Analysis and KOL Segmentation 22 i. KOL Peer Influence Values 22 1 Activity – Doctors, who reach more peers. 23 2 Critical Mass – Doctors, who convert more others. 23 3 Bridging Capital – Doctors, who translate and innovate better. 24 4 Network Values Interpretation – Whom to use best and for what? 25 ii. KOL Overall Influence Ranking – Top 25 Doctors 26 iii. KOL Segmentation – KOL Prioritization 27 1 Sectoral Hub Leads – Use for Peer Conversion (Vertical Influence) 27 2 Horizontal Leads – Use for Market Entry (Horizontal Influence) 28 3 Global Hub Leads – Use for Advocacy (Vertical & Horizontal Influence) 28 iv. KOL Segmentation – Network Visualization 28 v. KOL Segmentation – Detailed Network Environment and Role of each MD 30 vi. Most Influential KOL Ranking for each Role/Segment 36 VI. Key Opinion Leaders of Tomorrow and Rising KOLs 38 i. The Predictive Power of Dynamic Network Analysis 38 ii. Successful Career Profile Characteristics 38 1 Robust and Highly Influential KOLs 38 2 Rising KOLs and KOLs of Tomorrow 39 3 KOL Prioritization 39 iii. Rising KOL – Network Visualization 39 iv. Detailed Network Environment Maps of Rising KOLs and Robust Highly Influentials 41 v. Ranking: The best Rising KOLs & Stable Highly Influential KOLs 45 VII. Underlying Methodology - Social Network Analysis (SNA) 46 i. The Application of SNA in the Pharmaceutical Industry 46 ii. Social Network Analysis: History and Innovation 47 VIII. About the Underlying KOL Report 49 i. Corner Stones 49 ii. Potential Next Steps in Successful KOL Management 49 IX. About FAS.research 51 X. Appendix - Further Charts & Rankings 52 i. KOL Affinity Cluster Analysis – KOL Cluster Allocation 52 ii. Key Actor Analysis – KOL Overall Influence Ranking – Top 100 60 iii. Key Actor Analysis – KOL Ranking per Segment – Top 50 61 iv. Rising KOL/ KOL of Tomorrow Ranking - All 64 v. Robust Highly Influential KOL Ranking - All 65

Summary:

We all influence each other. Opinion, decision and innovation are formed in networks of patients, decision makers and experts. It's a decisive competitive advantage in terms of speed and costs to know key players and key links critical to your goal achievement, be it in your role as executive officer, medical director, marketing or product manager, or lobbyist. Different departments and companies turn to physicians to engage them as advisory board members, expert speakers, clinical investigators or consultants.

Companies Mentioned

- Dana-Farber Cancer Institute - Harvard Medical School - Harvard Public School of Health - NCI - National Cancer Institute - M.D. Anderson - Brigham & Women's Hospital - Keck School of Health - American Cancer Society - Yale Public School of Health - Yale Cancer Center - Mayo Clinic - UCLA - Vanderbilt Ingram - UC Irvine - UNC Chapel Hill - Group Health Center for Health Studies - MSKCC - Memorial Sloan-Kettering Cancer Center - James Graham Brown Cancer Center - Vermont Cancer Center